GeoVax is a biotechnology company specializing in human vaccines. The company is currently creating, developing, manufacturing and testing AIDS vaccines as well as conducting Phase 2 human clinical vaccine trials at multiple sites.

AIDS vaccines designed by GeoVax target predominant AIDS virus subtypes and use DNA and viral vector technologies. In Phase 1 Human Clinical Trial Testing on the AIDS vaccine, the vaccine demonstrated its ability to stimulate immune responses and was proven safe.

www.geovax.com